Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Coya Therapeutics (COYA) and the $15 Analyst Target: Is +400% Upside Realistic?

Coya Therapeutics (COYA) and the $15 Analyst Target: Is +400% Upside Realistic?

Key Takeaways

  • The central target of $15 is the arithmetic mean of six verified analyst price targets, which range from $12 to $18.
  • The latest verified price of roughly $2.95 implies a required upside of about 400% — a very large move.
  • The wide analyst range reflects a binary, data-driven biotech profile tied mainly to the lead candidate, COYA 302.
  • Enrollment in the Phase 2/3 ALSTARS ALS trial is complete, with topline data expected in early Q2 2027.
  • The biggest risks are clinical failure, widening losses, and the need for additional financing before commercialization.
  • For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
  • Interested in automated market analysis? Explore Trending AI Robots to see AI-driven strategies in action.

Breaking Down the Analyst Targets

Looking at the individual targets instead of just the headline number, the verified analyst price targets for COYA include $12 from Roth MKM, $18 from H.C. Wainwright, $17 from Lake Street, $16 from BTIG, $14 from Chardan Capital, and $15 from D. Boral Capital. These six targets produce an arithmetic mean of approximately $15.3, which rounds to a clean central target of $15. The low-to-high range spans $12 to $18, a spread of roughly 50%.

That dispersion matters. A clinical-stage company with no approved therapy derives most of its value from the probability that its lead program succeeds, so analysts assign different probabilities to the same binary outcome. The most cautious target ($12) still reflects substantial upside from current levels, while the highest target ($18) assumes a favorable readout and successful advancement. Analysts have overwhelmingly maintained Buy ratings, but there is no meaningful "consensus" beyond broad optimism about the pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where COYA Stands Today and the Road Ahead

As of the latest verified close, shares of COYA traded near $2.95, well below a 52-week range of roughly $2.72 to $6.62. Reaching a $15 price target would require an advance of approximately 400%, which is a very large move by any standard and typical of early-stage biotech, where value is concentrated in future clinical catalysts rather than current financials.

The path hinges almost entirely on the COYA 302 program for ALS. The ALSTARS Phase 2/3 trial completed enrollment with 137 participants, and the company expects topline data from the 24-week double-blind phase in early Q2 2027, with FTD biomarker data expected in Q1 2027. Coya ended Q3 2026 with about $35.8 million in cash, which management indicated should fund operations into the second half of 2027, past the ALSTARS readout. Revenue remains minimal and derived from a collaboration, not product sales.

Factors That Could Support a Move Toward the Target

  • Enrollment in the pivotal-stage ALSTARS trial is complete, de-risking the operational execution ahead of data.
  • COYA 302 holds an FDA Fast Track designation for ALS, a signal of regulatory interest in a high-unmet-need indication.
  • A broad Treg-focused pipeline, including exosome and cell-therapy platforms, offers optionality beyond the lead program.
  • The average analyst price target of roughly $15 sits far above the current price, reflecting a favorable risk-reward view among sell-side researchers.
  • Positive topline data would likely trigger a substantial repricing, given the limited current valuation.

Factors That Could Prevent the Target From Being Reached

  • Clinical failure or ambiguous ALSTARS data would invalidate the core thesis underpinning the higher targets.
  • Coya has no approved products and posted a widening Q3 2026 net loss of $10.6 million, or $0.45 per share, missing consensus estimates.
  • The company expects to need significant additional financing, which could dilute shareholders even on good news.
  • The stock has fallen sharply, reflecting weak sentiment and a market that may already be discounting execution and financing risk.
  • ALS remains a notoriously difficult indication, with a long history of late-stage trial failures across the industry.

Technical Levels and Market Structure

Shares of COYA have traded in a wide range between about $2.72 and $6.62 over the past year. The current price near the lower end of that band leaves limited obvious technical support below before multi-year lows, while any recovery would first need to reclaim the psychological $5 level and then the mid-$6 zone before the $12 target even enters view. Resistance in the single digits is largely defined by prior breakdown levels rather than durable demand zones, underscoring how much of the eventual move would depend on fundamental news flow.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms set their own assumptions, and biotech targets are unusually sensitive to single catalysts. The key events to watch are the FTD biomarker data expected in Q1 2027, the ALSTARS topline readout in early Q2 2027, any financing announcements, and analyst target revisions around those milestones. Quarterly cash-burn updates and regulatory interactions will also shape the risk-reward profile. From what I see, these catalysts will be the decisive inputs.

Exploring AI Daily Buy/Sell Signals for Context

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like COYA, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review alone. Consider exploring these signals to complement your own research.

Using Tickeron AI Tools in My Analysis

In my own work following names like this, I regularly use Tickeron’s AI Daily Buy/Sell Signals to cross-check sentiment shifts and technical setups around upcoming catalysts. The platform’s AI-driven approach helps surface patterns across thousands of securities without requiring hours of manual screening, which is especially useful for binary-event biotech stocks where timing around data readouts can matter a great deal. It has become a practical part of how I stay organized on volatile opportunities.

Final Assessment

The $15 central target for Coya Therapeutics represents the arithmetic mean of six analyst targets ranging from $12 to $18, and it sits roughly 400% above the latest price near $2.95 — a very large move that can only be justified by clinical success. The strongest supports are a fully enrolled pivotal ALS trial and a near-term catalyst calendar, while the principal obstacles are binary clinical risk, widening losses, and financing needs. Analysts broadly remain constructive, but their wide target range reflects genuine disagreement about the odds. Investors should monitor the FTD and ALSTARS data readouts and any capital-raising activity as the decisive inputs to whether the target becomes attainable. I’m watching this closely as the data milestones approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: COYA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


COYA's RSI Oscillator recovers from oversold territory

The RSI Indicator for COYA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 48 cases where COYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for COYA just turned positive on November 16, 2026. Looking at past instances where COYA's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.

Following a +3.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COYA as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for COYA entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.596). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5850 San Felipe Street
Phone
+1 800 587-8170
Employees
8
Web
https://www.coyatherapeutics.com
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.